Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Next Previous
Trial Profile

A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vinflunine (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pierre Fabre

Most Recent Events

  • 12 Oct 2014 According to UKCRN record, planned number of patients reported as 764.
  • 11 Jun 2014 Planned End Date changed from 1 Apr 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
  • 03 Jun 2014 Primary endpoint 'Progression-free-survival' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top